# Takara Bio

Source: https://onco.cc/companies/takara-bio/  
OnCo record `takara-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Takara Bio is a Japanese life-science tools company that also develops gene and cell therapies for cancer, including an oncolytic herpes virus and engineered T cells, and manufactures viral vectors for others.

## Summary

Takara Bio Inc., founded in 2002 and based in Kusatsu, Shiga, sells research reagents and contract manufactures viral vectors and cell therapies. Its own pipeline includes the oncolytic herpes simplex virus canerpaturev (C-REV), tested in phase 2 and 3 in pancreatic cancer and melanoma, and TCR- and CAR-engineered T cells developed with Japanese academic groups. Its trials are registered on ClinicalTrials.gov under Takara Bio as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Takara Bio Inc.; タカラバイオ
- Tags: ctgov-sponsor
- HQ: Kusatsu
- Type: cell-therapy
- Website: https://www.takara-bio.co.jp

## Sources

- Official website: https://www.takara-bio.co.jp
- ClinicalTrials.gov: trials led by Takara Bio Inc.: https://clinicaltrials.gov/search?lead=Takara%20Bio%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q11315991

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/), [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/), [Viral vector manufacturing (lentiviral, retroviral, AAV)](https://onco.cc/technologies/viral-vector-manufacturing/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/takara-bio.json